Key facts
- This page summarizes Alan B. Sandler's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Apr 2025, 16:19.
Alan B. Sandler - 11 Apr 2025 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ALXO
- Reported as of
- 11 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Apr 2025, 16:19:34 UTC
- Prior SEC filing
- 23 Jan 2025
- Next SEC filing
- 09 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelly Pinto, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan B. Sandler filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 15 Apr 2025.
Change
- Previous filing in this sequence was filed on 23 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALXO
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 11 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $0.4900
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
All of the shares subject to the option vest on April 11, 2026.